KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) FCF Margin (2016 - 2024)

Historic FCF Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Q4 2024 value amounting to 2957.46%.

  • Palvella Therapeutics' FCF Margin rose 13824000.0% to 2957.46% in Q4 2024 from the same period last year, while for Dec 2024 it was 8437.5%, marking a year-over-year increase of 84698300.0%. This contributed to the annual value of 2511.63% for FY2024, which is 25440400.0% up from last year.
  • As of Q4 2024, Palvella Therapeutics' FCF Margin stood at 2957.46%, which was up 13824000.0% from 2079.25% recorded in Q1 2024.
  • Palvella Therapeutics' 5-year FCF Margin high stood at 2957.46% for Q4 2024, and its period low was 2079.25% during Q1 2024.
  • In the last 5 years, Palvella Therapeutics' FCF Margin had a median value of 148.88% in 2021 and averaged 7.34%.
  • Per our database at Business Quant, Palvella Therapeutics' FCF Margin skyrocketed by 17961000bps in 2023 and then tumbled by -15297900bps in 2024.
  • Over the past 5 years, Palvella Therapeutics' FCF Margin (Quarter) stood at 745.6% in 2020, then soared by 82bps to 133.67% in 2021, then tumbled by -65bps to 221.04% in 2022, then soared by 813bps to 1575.06% in 2023, then surged by 88bps to 2957.46% in 2024.
  • Its FCF Margin was 2957.46% in Q4 2024, compared to 2079.25% in Q1 2024 and 1575.06% in Q4 2023.